Clinical trials: insulin glargine
Pre-diabetes
Study TO Prevent Diabetes With Short-term Insulin Glargine Only
Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as well as macrovascular and microvascular complication.
- Trial name
- STOP-GO (NCT01276912)
- Testing
- Insulin glargine, Lifestyle counseling
- Where
- China
- Volunteers
- 2,420 people
- Sponsor
- Beijing Tongren Hospital
Diabetes Mellitus, Type 2
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of…
- Trial name
- NCT00900146
- Testing
- Canakinumab, Metformin
- Where
- 106 sites in United States, Argentina and 12 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Diabetes Mellitus
Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes
Patients with diabetes treated with insulin often gain weight, which may deter patients from adhering to insulin treatment. Detemir is one type of long acting insulin approved by the Food and Drug Administration for use in people…
- Trial name
- NCT00659165
- Testing
- Insulin Detemir, Insulin Glargine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Type 2 Diabetes Mellitus
Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
The goal of the current study is to determine difference in glycemic control between traditional split mix regimen with Neutral Protamine Hagedorn (NPH) and regular insulin vs basal bolus regimen with glargine and humalog in a…
- Trial name
- NCT02189395
- Testing
- NPH and regular insulin, glargine and humalog
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Riverside University Health System Medical Center
Diabetes Mellitus, Type 2
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
Primary Objective: To demonstrate the superiority of insulin glargine over insulin NPH (Neutral Protamin Hagedornon) the change in HbA1c from baseline to the end of the treatment period.
- Trial name
- LANCELOT (NCT00949442)
- Testing
- Insulin Glargine (HOE901) [Lantus], Glimepiride, human insulin [NPH]
- Where
- 87 sites in Brazil, Czechia and 15 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look…
- Trial name
- NCT05013229
- Testing
- IcoSema, Insulin glargine, insulin aspart
- Where
- 182 sites in United States, Czechia and 12 more
- Volunteers
- 679 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2…
- Trial name
- onset® 2 (NCT01819129)
- Testing
- Faster-acting insulin aspart, Insulin aspart, Insulin glargine
- Where
- 144 sites in United States, Canada and 8 more
- Volunteers
- 881 people
- Sponsor
- Novo Nordisk A/S
Diabetic Ketoacidosis
Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis
The purpose of this study is to determine whether adult DKA patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous…
- Trial name
- NCT02930044
- Testing
- Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus
The objectives of this clinical trial are to compare the effects of exenatide once weekly and insulin glargine on blood glucose control, body weight, lipids, safety, and tolerability.
- Trial name
- NCT00935532
- Testing
- exenatide once weekly, insulin glargine
- Where
- 22 sites in Japan
- Volunteers
- 427 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.
This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin…
- Trial name
- GRANT (NCT06999551)
- Testing
- switch NPH to glargin
- Where
- Tunisia
- Volunteers
- 60 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Diabetes Mellitus, Type 2
Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by treatment with once daily basal…
- Trial name
- SeLan (NCT01234597)
- Testing
- INSULIN GLARGINE (HOE901), INSULIN GLULISINE (HMR1964)
- Where
- 11 sites in Israel
- Volunteers
- 219 people
- Sponsor
- Sanofi
Type1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.
- Trial name
- NCT01357603
- Testing
- Glargine
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Wockhardt
Type 2 Diabetes Mellitus
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
Primary Objective: To evaluate the safety of Gla-300 in insulin naïve T2D participants uncontrolled on oral antihyperglycemic drugs Secondary Objective: To assess the efficacy of Gla-300 on glycemic control in insulin naïve T2D…
- Trial name
- SAFEGUARD (NCT04980027)
- Testing
- Insulin glargine (U300)
- Where
- 2 sites in India
- Volunteers
- 228 people
- Sponsor
- Sanofi
Type 2 Diabetes
Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes
This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and their effect on blood glucose control, versus…
- Trial name
- NCT00971659
- Testing
- insulin glargine + exenatide + preexisting metformin, insulin glargine + sitagliptin + preexisting metformin, insulin glargine + preexisting metformin
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus Type 1
A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine
This trial will compare the metabolic control in type 1 diabetes obtained by continuous infusion of insulin lispro with that obtained by multiple daily injections of insulin lispro and glargine, a long-acting insulin analogue.
- Trial name
- NCT00468754
- Testing
- Insulin pumps
- Where
- 4 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
Randomized Transition to Gla-300 in Pediatric Type 1 Diabetes: CGM-Derived Outcomes
This study evaluated two different starting dose strategies when switching children and adolescents with type 1 diabetes from insulin glargine U-100 to insulin glargine U-300.
- Trial name
- NCT07872475
- Testing
- Insulin glargine U-300
- Where
- Turkey (Türkiye)
- Volunteers
- 71 people
- Sponsor
- Marmara University
Diabetes Mellitus, Type 2
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.
- Trial name
- NCT01175811
- Testing
- Insulin Lispro Premix, Insulin Glargine, Insulin Lispro
- Where
- 14 sites in China, South Korea and 1 more
- Volunteers
- 402 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
Insulin Schemes for Type 2 Diabetes Control
The aim of the study is to determine differences in glycemic control between a basal-bolus scheme insulin and NPH scheme insulin in a population of hospitalized patients with type 2 diabetes in a Noncritical Care Facility in…
- Trial name
- NCT03350984
- Testing
- NPH insulin, Glargine and Lispro insulin
- Where
- Mexico
- Volunteers
- 75 people
- Sponsor
- Universidad de Guanajuato
Type 1 Diabetes Mellitus
Prevention of Severe Hypoglycemia in Type 1 Diabetes
Severe hypoglycaemia leading to collapse without warning is one of the most-feared complications for those with Type 1 diabetes.
- Trial name
- NCT00360984
- Testing
- insulin glargine, continuous subcutaneous insulin infusion
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Newcastle University